Company intelligence / Profile preview

Bionic Sight

New York, New York, United Statesbionicsightllc.com ↗

Ownership: Private
Development stage: Phase 1

Overview

BS01 gene therapy received RMAT designation from FDA in February 2025 for treatment of retinitis pigmentosa patients with advanced stage vision loss. The company reported "potentially game changing results" in its Phase 1/2 trial and is now preparing for Phase 3 trials.

Therapeutic areas: Ophthalmology
Modalities: Gene therapyOptogenetics
Industry: Biotech

Drug pipeline

1 asset

BS01

Partnerships

Applied Genetic Technologies Corporation (AGTC)

Beyond the preview

Go deeper on Bionic Sight.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bionic Sight.

Explore the full profile